We next tested the impact of pharmacological intervention with PI3K/Akt or RhoA/ROCK signalling on p110αH1047R-induced centrosomal abnormalities, either before their genesis in primary cells or once they had been established in a tumour context. The gene discussed is PIK3CA; the disease is neoplasm.